Basal Cell Carcinoma Treatment Market To Reach $5.93 Billion By 2030

Basal Cell Carcinoma Treatment Market Growth & Trends

The global basal cell carcinoma treatment market size is anticipated to reach USD 5.93 billion by 2030, growing at a CAGR of 10.44% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of basal cell carcinoma and the rising geriatric population. The European Skin Cancer Foundation estimates that the incidence of basal cell carcinoma (BCC) is 50 to 80 new cases per 100,000 people in Europe and 250 cases per 100,000 people in Australia annually, with an increasing trend. The increase in the number of cancer cases can primarily be attributed to the growing overall & geriatric population and certain socioeconomic factors.

Technological advancement in the diagnosis and treatment of disease is anticipated to positively impact market growth. With advanced technologies, dermatologists can more accurately diagnose patients and effectively differentiate basal cell carcinoma from other skin lesions. For instance, in 2024, the U.S. FDA approved DermaSensor, an AI-powered light spectroscopy instrument for detecting skin cancer, including melanoma, single cell carcinoma (SCC), and basal cell carcinoma (BCC). This technique can help primary care clinicians identify patients who require rapid attention for a biopsy and specialist care, thereby alleviating high wait times and the shortage of dermatologists in certain places. The growing use of such diagnostic tools is expected to increase the diagnostic and treatment rates in the future, driving demand for medicines used for the treatment of basal cell carcinoma.

Furthermore, the increase in the geriatric population is driving the demand for treatment of BCC, including surgery, radiotherapy, topical chemotherapy, oral medications, and chemical peeling. The main cause of developing BCC is repeated exposure to Ultraviolet (UV) light. The elderly population has a higher chance of acquiring BCC than younger people as they have been exposed to UV rays for longer during their lifetime. Due to aging and reduced immune system function, UV radiation and other carcinogenic factors can break the DNA more easily, increasing the risk of skin cancer, especially BCC, in older persons. According to a study published in the Journal of Geriatric Oncology in 2023, over 100,000 patients with BCC are treated annually in their final year of life in the U.S. However, clinical practice guidelines hardly ever take age & comorbidities into account. Thus, a growing geriatric population is expected to drive market growth during the forecast period.

 Request a free sample copy or view report summary: Basal Cell Carcinoma Treatment Market Report

Basal Cell Carcinoma Treatment Report Highlights

• The surgery segment held the largest revenue share of the market in 2023. This can be attributed to the increasing incidence and prevalence of disease and the high demand for surgery for treatment owing to high safety and efficacy.

• In topical chemotherapy, the 5-fluorouracil (5-FU) segment held the largest share of the market in 2023. This can be attributed to the development and launch of a novel generic version of 5-fluorouracil (5-FU) to treat BCC patients.

• North America dominated the market owing to factors such as advanced healthcare infrastructure, increasing prevalence of basal cell carcinoma, and favorable regulatory environment for R&D of novel products.

Basal Cell Carcinoma Treatment Market Segmentation

Grand View Research has segmented the global basal cell carcinoma treatment market based on the treatment type, and region:

Basal Cell Carcinoma Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Surgery

  • Mohs surgery

  • Surgical Excision

  • Electrodesiccation and Curettage (ED&C)

• Radiotherapy (RT)

• Intralesional injections

• Topical chemotherapy

  • 5-fluorouracil (5-FU)

  • Tirbanibulin (Klisyri)

  • Imiquimod (Zyclara)

• Oral Medications

  • Vismodegib (Erivedge)

  • Sonidegib (Odomzo)

• Intravenous Medications

• Chemical peeling treatment

Basal Cell Carcinoma Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • Kuwait

  • UAE

List of Key Players in the Basal Cell Carcinoma Treatment Market

• Bausch Health Companies Inc.

• Almirall, S.A.

• Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)

• Novartis AG

• Regeneron Pharmaceuticals Inc.

• Dr Reddy’s Laboratories

• Taro Pharmaceuticals Ltd

• Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)